GLP-1glp-1 receptor agonistspancreatitistype 2 diabetessafety

Review finds no excess recurrent pancreatitis with GLP-1 agonists after prior attack

Four studies covering 10,624 patients showed lower odds of recurrence versus placebo and versus SGLT2 inhibitors, though only two provided comparative data.

By Maren Holt · Senior Reporter, GLP-1

Oct 13 20:00 ETSource: Acta diabetologica

The wire

01In Acta Diabetologica, a systematic review of four studies and 10,624 patients, 5,427 on GLP-1 receptor agonists, found recurrent acute pancreatitis odds of 0.26 (95% CI 0.05-1.32) versus placebo and 0.57 (0.52-0.64) versus SGLT2 inhibitors.
02Prior acute pancreatitis is a common reason clinicians withhold incretin therapy in type 2 diabetes and obesity; these pooled data do not show an increased recurrence signal.
03Two single-arm studies reported recurrence rates of 9.9% and 11.9% among GLP-1 users. Comparative evidence came from only two studies, and the authors urge cautious interpretation.

From the source

Risk of recurrent acute pancreatitis with GLP-1 receptor agonists after prior pancreatitis: a systematic review
Acta diabetologica · 2026 Oct 14 · Voltani DL, Pinto FG, Holland S et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42873314/